Description

Tesamorelin is a synthetic peptide that stimulates endogenous growth hormone release via the GHRH pathway. Unlike direct hormone administration, Tesamorelin works by activating the body’s natural regulatory mechanisms.

Tesamorelin is FDA-approved for the reduction of excess visceral adipose tissue. Visceral fat is metabolically active fat stored deep within the abdominal cavity and is regulated differently than subcutaneous fat.

Research has shown that growth hormone signaling plays a role in lipolysis, the biological process by which stored fat is mobilized into usable energy. Through its stimulation of growth hormone release, Tesamorelin has been studied for its effects on visceral fat metabolism and body composition–related pathways.

Beyond its approved indication, Tesamorelin continues to be explored in research settings for its broader relationship to metabolic signaling, hormonal regulation, and system-level balance.